Archive for the ‘Uncategorized’ Category

Sussex Research Acquires Chemaphor Chemical Services from Avivagen

Thursday, October 12th, 2017

Ottawa, Canada October 13, 2017 – Sussex Research Laboratories Inc. (Sussex Research), the leading specialist in the synthesis of carbohydrate and stable isotope-labeled molecules, is pleased to announce the successful acquisition of Chemaphor Chemical Services (“Chemaphor”) and its product portfolio from Avivagen Inc. The acquisition strengthens the company’s capabilities and product offering of high-purity stable isotope-labeled products, particularly Vitamin D and E, for use in biological research, drug discovery, medical diagnostic, food and dairy testing and other laboratory applications.

Dr. Brady Clark, Founder & CEO of Sussex Research comments: “Chemaphor has been providing very high purity stable isotope-labeled products and custom synthesis services relating to vitamins for nearly two decades. The acquisition of Chemaphor, its products and its chemists is an important step in further enhancing the global leadership of Sussex Research in the demanding fields of carbohydrate and stable isotope-labeling of bioorganic molecules and small molecule API. This strengthens our position in international R&D markets and also provides immediate access to additional production capacity for our growing product/project portfolios.”

Dr. Graham Burton, cofounder and Chief Scientific Officer at Avivagen Inc., continues: “Keith Ingold and I pioneered use of stable isotope-labeled vitamin E in research dating back several decades. Chemaphor has been an important part of Avivagen’s growth. Nevertheless, Avivagen is now fully committed to commercializing our animal health supplement products. I’m very pleased that Sussex Research can provide its full attention to these high quality labelled products. This is a great opportunity for the former Chemaphor staff to join the international leader in carbohydrate synthesis and stable isotope-labeling, where there will be ample opportunity to expand the product portfolio, expand contract research and development while also gaining access to a wider marketing effort.”

About Avivagen

Avivagen is developing and commercializing products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal’s own health defences. The Corporation’s unique, proprietary technology is known as OxC-beta™ (fully-oxidized beta-carotene) technology.

About Sussex Research

Sussex Research is a contract research organization and leading specialist in the design, synthesis and characterization of carbohydrate-based systems and stable isotope-labeled molecules. We excel at synthesis of molecules that incorporate elements of carbohydrates, glycans and polysaccharides. Our product portfolio and contract synthesis services enable our clients and partners to explore and exploit glycosylation or stable isotope-labeling for drug discovery, drug delivery, carbohydrate-based vaccine development, therapeutic enhancement and bio-analytical assay development.

Contact:

For further questions, please visit our websites or contact the person below.

Sussex Research Laboratories Inc.
Brady Clark, Ph.D., CEO
Tel.: 1 613 993 4402
Fax: 1 613 949 5993
info@sussex-research.com
www.sussex-research.com

Avivagen Inc.
Munawara Dar, Administrator
Tel: 1 613 949 8164
Fax: 1 613 993 0796
m.dar@avivagen.com
www.avivagen.com

Sussex Research Receives Notice of Allowance for Glycopeptide Cosmetic Active Technology Patent

Thursday, October 12th, 2017

OTTAWA, Canada, September 21, 2017 – Sussex Research Laboratories Inc. (“Sussex Research”), the leading specialist in carbohydrate synthesis, glycosylation and glycodesign, is pleased to announce that the U.S. Patent and Trademark Office has issued a Notice of Allowance for U.S. Patent Application No. 15/103,452 entitled “GLYCOPEPTIDE COMPOSITIONS AND USES THEREOF.” The patent covers the Company’s novel cosmetic active ingredient, GlycolastinTM, a glycosylated peptide developed as an anti-wrinkling cosmetic active that efficiently improves the appearance of fine lines and wrinkles while also increasing skin hydration and elasticity. In vitro studies have shown that GlycolastinTM stimulates at least 3 major constituents of skin that are all important for the maintenance of healthy skin. In vivo studies demonstrated that, within 42 days, crow’s feet wrinkles were visibly decreased while also improving skin hydration and elasticity.

Dr. Brady Clark, President and Chief Executive Officer stated: “This is the first of what we hope will be several patents that we expect to receive to protect our GlycolastinTM technology which utilizes glycosylation to improve the effectiveness of cosmetic peptide actives. We expect finished products that utilize this unique active to be introduced in 2018.”

About Glycolastin™

Glycolastin™has been developed by Sussex Research to exploit the field of glycobiology in order to advance a new and state-of-the-art anti-aging technology. In vitro studies have shown that Glycolastin™ is significantly more efficient at stimulating structural protein synthesis in skin cells than the non-glycosylated peptide active, a well-known peptide active in the cosmetics field. Increased secretion of structural proteins elastin, fibronectin and collagens by fibroblasts was observed in vitro for glycosylated peptides compared to the non-glycosylated reference peptide. The in vitro effect on elastin secretion has also been confirmed independently in a 3D ex vivo skin model. Patents have been filled in numerous jurisdictions.

About Sussex Research:

Sussex Research is a contract research organization and leading specialist in the design, synthesis and characterization of carbohydrate-based systems and stable isotope-labeled molecules. We excel at synthesis of molecules that incorporate elements of carbohydrates, glycans and polysaccharides. Our product portfolio and contract synthesis services enable our clients and partners to explore and exploit glycosylation or stable isotope-labeling for drug discovery, drug delivery, carbohydrate-based vaccine development, therapeutic enhancement and bio-analytical assay development. For more information visit www.sussex-research.com.

 

 

Sussex Research Announces Successful Clinical Trial Results for Glycolastin(TM) its novel anti-aging glycopeptide cosmetic active.

Thursday, October 12th, 2017

OTTAWA, Canada, August 17, 2015 – Sussex Research Laboratories Inc. (“Sussex Research”), the leading specialist in carbohydrate synthesis, glycosylation and glycodesign, is pleased to announce that its clinical trial for GlycolastinTM, an anti-aging glycopeptide cosmetic active, has successfully concluded. The in vivo study involved 26 healthy female volunteers between 37-67 years of age. The study was a monocentric open-label trial carried out by Evalulab Inc. of Montreal, Canada.

Dermal irritation patch (48hrs) and HRIPT tests revealed that the active may be considered a non-irritant and hypo-allergenic. The formulated Glycolastin™ test product was also very well tolerated over the 42D study period. According to the results reported in this study, Glycolastin™ may be considered as an effective and novel anti-aging ingredient demonstrating significant improvement in skin firmness, hydration and profilometry results (reduction of fine lines, moderate and deep wrinkles). A few results are summarized below:

Fine Lines (Class 1) – significant reduction of 24% (p<0.01) in the number of wrinkles at 42 days with maximal reduction up to 74%

Medium Wrinkles (Class 2) – significant reduction of 16% (p<0.01) at 42 days with effectiveness up to 76%

Deep Wrinkles (Class 3) – significant decrease by 27% (p<0.01) at 42 days with maximal observed improvement of 86%

Dr. Brady Clark, Founder & CEO of Sussex Research comments: “We are very excited that our scientific studies translated to this excellent result in the clinic. It was the dramatic observations made during in vitro and ex vivo studies that prompted us to patent the glycopeptide technology and undertake the clinical trial. As a company that has worked with numerous partners on glycosylation of peptides and other biological molecules, we have known for many years that glycosylation can markedly improve the effectiveness of peptides and other biological molecules. It’s very gratifying to show that glycosylation can be very useful for cosmetic actives as well.”

Plans are underway to commercialize GlycolastinTM as a cosmetic active in topical anti-aging products.

About Glycolastin™

Glycolastin™has been developed by Sussex Research to exploit the field of glycobiology in order to advance a new and state-of-the-art anti-aging technology. In vitro studies have shown that Glycolastin™ is significantly more efficient at stimulating structural protein synthesis in skin cells than the non-glycosylated peptide active, a well-known peptide active in the cosmetics field. Increased secretion of structural proteins elastin, fibronectin and collagens by fibroblasts was observed in vitro for glycosylated peptides compared to the non-glycosylated reference peptide. The in vitro effect on elastin secretion has also been confirmed independently in a 3D ex vivo skin model. Patents have been filled in numerous jurisdictions.

About Sussex Research:

As a leading specialist in glycodesign and the synthesis of complex carbohydrates, Sussex Research excels at the discovery and development of molecules that explore and exploit glycobiology. Sussex Research excels in the design, synthesis and characterization of molecules that incorporate glycotechnology. Our unique product portfolio and carbohydrate synthesis capabilities enable researchers across a variety of scientific disciplines to readily explore and exploit glycobiology in order to enhance the therapeutic potential of small molecules, peptides, proteins, lipids and oligonucleotides. For more information visit www.sussex-research.com.

Sussex Research Presents Data on “Post Translationally Modified Cosmeceutical Actives” at the International Federation of Societies for Cosmetic Chemists (IFSCC) Congress in Paris.

Thursday, October 12th, 2017

Paris, France, October 28, 2014 – Sussex Research scientists presented data on the Company’s promising research & development program on carbohydrate-based anti-aging actives. Sussex Research scientists presented the latest results on the Company’s anti-aging carbohydrate-based molecules at the International Federation of Societies for Cosmetic Chemists Congress in Paris, France. The poster, entitled “Post Translationally Modified Cosmeceutical Actives,” was extremely well received.

About Sussex Research: As a leading specialist in glycodesign and the synthesis of complex carbohydrates, Sussex Research excels at the discovery and development of molecules that explore and exploit glycobiology. Sussex Research excels in the design, synthesis and characterization of molecules that incorporate glycotechnology. Our unique product portfolio and carbohydrate synthesis capabilities enable researchers across a variety of scientific disciplines to readily explore and exploit glycobiology in order to enhance the therapeutic potential of small molecules, peptides, proteins, lipids and oligonucleotides. For more information visit www.sussex-research.com.

Sussex Research Collaborator Receives Grant to Develop Glycan-Labelled BODIPY Fluorophores For Use In Glycobiology

Friday, September 5th, 2014

Ottawa, Canada, September 5, 2014 – Sussex Research Laboratories Inc. announced today that Professor Hongbin (Tony) Yan of Brock University has received an NSERC Engage grant for a project entitled Labelling glycans with BODIPY fluorophores.

BODIPY fluorophores possess a number of unique properties that have led to their increasing popularity in a wide range of applications. Compared with other commercially available fluorophores such as fluoresceins, rhodamines, and cyanines, BODIPY fluorophores are in general more stable, both chemically and photochemically. Moreover, BODIPY fluorescent properties are relatively pH- and environment-independent, which is a very useful feature in many applications.

The project is expected to combine Sussex Research expertise in the preparation of glycoconjugates and glycans having functionalized linker/spacer systems with the Brock team’s capabilities in BODIPY chemistry. The project is expected to result in a new class of BODIPY fluorophore functionalized carbohydrate-based products.for use in the fields of molecular biology and glycobiology.

According to Brady Clark, President & CEO of Sussex Research, “As industrial partner on the project, Sussex Research is very pleased to support Professor Yan and his research team. The Yan laboratory are experts in BODIPY chemistry with a proven track record of working with BODIPY. This collaboration will extend the novel product portfolio of Sussex Research and make BODIPY-labelled glycans available to researchers worldwide.”

About Sussex Research: As a leading specialist in glycodesign and the synthesis of complex carbohydrates, Sussex Research excels at the discovery and development of molecules that explore and exploit glycobiology. Sussex Research excels in the design, synthesis and characterization of molecules that incorporate glycotechnology. Our unique product portfolio and carbohydrate synthesis capabilities enable researchers across a variety of scientific disciplines to readily explore and exploit glycobiology in order to enhance the therapeutic potential of small molecules, peptides, proteins, lipids and oligonucleotides. For more information visit www.sussex-research.com.